JP2014530801A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530801A5
JP2014530801A5 JP2014517060A JP2014517060A JP2014530801A5 JP 2014530801 A5 JP2014530801 A5 JP 2014530801A5 JP 2014517060 A JP2014517060 A JP 2014517060A JP 2014517060 A JP2014517060 A JP 2014517060A JP 2014530801 A5 JP2014530801 A5 JP 2014530801A5
Authority
JP
Japan
Prior art keywords
acid
oral administration
liquid
administration according
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530801A (ja
JP6077534B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2012/077668 external-priority patent/WO2013058411A1/en
Publication of JP2014530801A publication Critical patent/JP2014530801A/ja
Publication of JP2014530801A5 publication Critical patent/JP2014530801A5/ja
Application granted granted Critical
Publication of JP6077534B2 publication Critical patent/JP6077534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517060A 2011-10-19 2012-10-19 経口投与用液剤 Active JP6077534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548859P 2011-10-19 2011-10-19
US61/548,859 2011-10-19
PCT/JP2012/077668 WO2013058411A1 (en) 2011-10-19 2012-10-19 Solution for oral administration

Publications (3)

Publication Number Publication Date
JP2014530801A JP2014530801A (ja) 2014-11-20
JP2014530801A5 true JP2014530801A5 (https=) 2015-12-03
JP6077534B2 JP6077534B2 (ja) 2017-02-08

Family

ID=47178263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517060A Active JP6077534B2 (ja) 2011-10-19 2012-10-19 経口投与用液剤

Country Status (35)

Country Link
US (8) US20140303183A1 (https=)
EP (1) EP2768508B1 (https=)
JP (1) JP6077534B2 (https=)
KR (1) KR101856283B1 (https=)
CN (2) CN107823131A (https=)
AR (1) AR088372A1 (https=)
AU (2) AU2012326978B2 (https=)
BR (1) BR112014009330A2 (https=)
CA (1) CA2851999C (https=)
CL (1) CL2014000967A1 (https=)
CO (1) CO6950486A2 (https=)
CY (1) CY1117794T1 (https=)
DK (1) DK2768508T3 (https=)
EA (2) EA201490812A1 (https=)
ES (1) ES2583137T3 (https=)
HR (1) HRP20160989T1 (https=)
HU (1) HUE028869T2 (https=)
IL (1) IL231988A (https=)
IN (1) IN2014DN02987A (https=)
JO (1) JO3190B1 (https=)
LT (1) LT2768508T (https=)
ME (1) ME02459B (https=)
MX (1) MX347309B (https=)
MY (1) MY169096A (https=)
PH (1) PH12014500816A1 (https=)
PL (1) PL2768508T3 (https=)
PT (1) PT2768508T (https=)
RS (1) RS54967B1 (https=)
SG (1) SG11201401273SA (https=)
SI (1) SI2768508T1 (https=)
SM (1) SMT201600341B (https=)
TW (2) TWI679977B (https=)
UA (1) UA111506C2 (https=)
WO (1) WO2013058411A1 (https=)
ZA (1) ZA201402669B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
RU2633635C1 (ru) * 2016-06-29 2017-10-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
WO2017095266A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения (варианты)
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
RU2627423C1 (ru) * 2016-06-29 2017-08-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
US11013702B2 (en) * 2017-10-10 2021-05-25 Vertice Pharma, Llc Midodrine hydrochloride oral solution and uses thereof
JPWO2021029020A1 (https=) * 2019-08-13 2021-02-18
JP2021115288A (ja) * 2020-01-28 2021-08-10 青葉化成株式会社 液状組成物および液状医療材料
CA3184420A1 (en) 2020-06-30 2022-01-06 Mark C. Faulkner Compositions and methods for treatment of vaginal infections
US20210401879A1 (en) * 2020-06-30 2021-12-30 Vireo Systems, Inc. Compositions for controlling odor and itch and methods of and devices for administering same
WO2022218356A1 (zh) * 2021-04-13 2022-10-20 上海博志研新药物技术有限公司 一种布瑞哌唑口溶膜组合物、其制备方法及应用
CN115414322A (zh) * 2022-07-05 2022-12-02 杭州民生药物研究院有限公司 一种富马酸卢帕他定口服液体制剂及其制备工艺
CN116966140A (zh) * 2023-08-18 2023-10-31 四川阿赛斯生物科技有限公司 一种含有布瑞哌唑的口服溶液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420077A (en) * 1972-04-14 1976-01-07 Unilever Ltd Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AU2003223093B2 (en) * 2002-05-03 2010-02-04 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
JP5041279B2 (ja) * 2004-04-22 2012-10-03 株式会社 Mbr 細菌細胞壁骨格成分を含有する製剤
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US8283352B2 (en) * 2005-06-13 2012-10-09 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
CN101257890B (zh) * 2005-09-01 2012-10-31 巴克斯特国际公司 含有酸作为增溶剂的阿加曲班制剂
US20100004267A1 (en) * 2006-07-31 2010-01-07 Asubio Pharma Co., Ltd. Liquid preparation
EP2200584A2 (en) * 2007-09-17 2010-06-30 Schering Corporation Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
WO2009039324A1 (en) 2007-09-21 2009-03-26 Forest Laboratories Holdings Limited Soluble dosage forms containing cephem derivatives suitable for parenteral administration
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
NZ603076A (en) * 2010-08-24 2014-12-24 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyril derivative and silicone oil and/or silicone oil derivative
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組,以及彼之用途

Similar Documents

Publication Publication Date Title
JP2014530801A5 (https=)
JP2011201907A5 (https=)
EA201490812A1 (ru) Раствор для перорального введения
JP2015527402A5 (https=)
JP2014534222A5 (https=)
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
JP2017214429A5 (https=)
JP2015098469A5 (https=)
JP2013513612A5 (https=)
CA2717605A1 (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
JP2014129360A5 (https=)
ZA201508924B (en) Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
JP2016539921A5 (https=)
EA201291089A1 (ru) Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
CA2920410C (en) Thienopiperidine derivative and use thereof
RU2012113844A (ru) Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
JP2015505295A5 (https=)
WO2015001163A3 (es) Nanopartículas lipídicas para la cicatrización de heridas
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
HRP20200829T1 (hr) Farmaceutski pripravak u obliku oralne suspenzije koja uključuje flavonoidnu frakciju i ksantansku gumu
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
NZ731518A (en) Formulations of a pi3k/mtor-inhibitor for intravenous administration
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone